HomeComparePTLKF vs ABBV

PTLKF vs ABBV: Dividend Comparison 2026

PTLKF yields 400000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PTLKF wins by $5.011119029548644e+32M in total portfolio value
10 years
PTLKF
PTLKF
● Live price
400000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011119029548644e+32M
Annual income
$500,865,583,351,836,840,000,000,000,000,000,000,000.00
Full PTLKF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PTLKF vs ABBV

📍 PTLKF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPTLKFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PTLKF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PTLKF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PTLKF
Annual income on $10K today (after 15% tax)
$34,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, PTLKF beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PTLKF + ABBV for your $10,000?

PTLKF: 50%ABBV: 50%
100% ABBV50/50100% PTLKF
Portfolio after 10yr
$2.505559514774322e+32M
Annual income
$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PTLKF
No analyst data
Altman Z
1.1
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PTLKF buys
0
ABBV buys
0
No recent congressional trades found for PTLKF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPTLKFABBV
Forward yield400000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$5.011119029548644e+32M$102.3K
Annual income after 10y$500,865,583,351,836,840,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$5.010957816668433e+32M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PTLKF vs ABBV ($10,000, DRIP)

YearPTLKF PortfolioPTLKF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$40,010,700$40,000,000.00$11,550$430.00+$40.00MPTLKF
2$149,615,521,729$149,572,710,280.37$13,472$627.96+$149615.51MPTLKF
3$522,880,052,725,200$522,719,964,116,949.25$15,906$926.08+$522880052.71MPTLKF
4$1,707,862,989,289,045,000$1,707,303,507,632,628,700.00$19,071$1,382.55+$1707862989289.03MPTLKF
5$5,213,509,402,845,684,000,000$5,211,681,989,447,144,000,000.00$23,302$2,095.81+$5213509402845684.00MPTLKF
6$14,874,219,058,409,543,000,000,000$14,868,640,603,348,497,000,000,000.00$29,150$3,237.93+$14874219058409543680.00MPTLKF
7$39,661,196,234,050,755,000,000,000,000$39,645,280,819,658,260,000,000,000,000.00$37,536$5,121.41+$3.966119623405075e+22MPTLKF
8$98,838,436,350,327,300,000,000,000,000,000$98,795,998,870,356,880,000,000,000,000,000.00$50,079$8,338.38+$9.88384363503273e+25MPTLKF
9$230,205,236,474,344,900,000,000,000,000,000,000$230,099,479,347,450,050,000,000,000,000,000,000.00$69,753$14,065.80+$2.302052364743449e+29MPTLKF
10$501,111,902,954,864,400,000,000,000,000,000,000,000$500,865,583,351,836,840,000,000,000,000,000,000,000.00$102,337$24,771.77+$5.011119029548644e+32MPTLKF

PTLKF vs ABBV: Complete Analysis 2026

PTLKFStock

PT Lippo Karawaci Tbk, together with its subsidiaries, provides property development services in Indonesia. It operates in three segments: Real Estate Development, Real Estate Management & Services, and Fund Management/Investments. The Real Estate Development segment is involved in the real estate activities, including urban development; development of facilities and its infrastructure; large scale integrated and infrastructure development projects, such as residential condominiums, commercial and entertainment areas, office space, and healthcare and education facilities; food business; and other investments. The Real Estate Management & Services segment develops and manages shopping center; operates hotels, recreation centers, and restaurants; provides health, town management, and water and sewage treatment services; and offers transportation and maintenance services. The Fund Management/Investments segment provides management services. The company provides financial, professional, scientific, and technical services; construction, transportation, trading, water management and treatment, wastewater management, waste management and recycling, parking, remediation, employment, and other supporting services, as well as hospital, clinic, health center, polyclinic, and other related services. In addition, it engages in investment, development, printing, agriculture, gardening, workshop, pharmaceutical wholesale, mining, computer programming, other management consulting, hotel management, township development, asset management, home care, and air installation activities. As of December 31, 2021, it operated 40 hospitals; 59 malls, including 49 leased and 10 strata-titled malls; and 10 hotels. The company was formerly known as PT Tunggal Reksakencana. PT Lippo Karawaci Tbk was founded in 1990 and is headquartered in Tangerang, Indonesia.

Full PTLKF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PTLKF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PTLKF vs SCHDPTLKF vs JEPIPTLKF vs OPTLKF vs KOPTLKF vs MAINPTLKF vs JNJPTLKF vs MRKPTLKF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.